Difference between right-sided and left-sided colorectal cancers: from embryology to molecular subtype

Expert Review of Anticancer Therapy

Volumn 18, Issue 4, 2018, Pages 351-358

  Yang, Seung Yoon ^a   Cho, Min Soo ^a   Kim, Nam Kyu ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Colorectal cancer; hindgut; location; metastatic; midgut; prognostic

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER SCREENING; CHROMOSOMAL INSTABILITY; EMBRYOLOGY; ENVIRONMENTAL FACTOR; FUNCTIONAL ANATOMY; GENETIC DIFFERENCE; GENOTYPE; HUMAN; LEFT SIDED COLORECTAL CANCER; METASTATIC COLORECTAL CANCER; MICROBIOME; MISMATCH REPAIR; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; REVIEW; RIGHT SIDED COLORECTAL CANCER; ANIMAL; COLON TUMOR; COLORECTAL TUMOR; GENETICS; MASS SCREENING; METASTASIS; PATHOLOGY; PROCEDURES; RECTUM TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; HUMANS; MASS SCREENING; NEOPLASM METASTASIS; RECTAL NEOPLASMS;

EID: 85044052572     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1080/14737140.2018.1442217     Document Type: Review

References (68)

1. Hinoue T, Weisenberger DJ, Lange CP, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012;22(2):271–282.
2. Ogino S, Galon J, Fuchs CS, et al. Cancer immunology–analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011;8(12):711–719.
3. Iacopetta B., Are there two sides to colorectal cancer? Int J Cancer. 2002;101(5):403–408.
4. Carethers JM., One colon lumen but two organs. Gastroenterology. 2011;141(2):411–412.
5. Shen H, Yang J, Huang Q, et al. Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World J Gastroenterol. 2015;21(21):6470–6478.
6. Saidi HS, Karuri D, Nyaim EO. Correlation of clinical data, anatomical site and disease stage in colorectal cancer. East Afr Med J. 2008;85(6):259–262.
7. Breivik J, Lothe RA, Meling GI, et al. Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors. Int J Cancer. 1997;74(6):664–669.
8. Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713–1729.
9. Holch JW, Ricard I, Stintzing S, et al. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer. 2017;70:87–98.
10. Stintzing S, Tejpar S, Gibbs P, et al. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. Eur J Cancer. 2017;84:69–80.
11. Schoenwolf GC, Bleyl SB, Brauer PR, et al. Larsen’s human embryology E-Book. Elsevier Health Sciences; 2014.
12. Hill M. Embryology gastrointestinal tract development. 2016.
13. Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–193.
14. Cheng L, Eng C, Nieman LZ, et al. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol. 2011;34(6):573–580.
15. McDevitt J, Comber H, Walsh PM. Colorectal cancer incidence and survival by sub-site and stage of diagnosis: a population-based study at the advent of national screening. Ir J Med Sci. 2017;186(1):113–121.
16. Park HM, Woo H, Jung SJ, et al. Colorectal cancer incidence in 5 Asian countries by subsite: an analysis of Cancer Incidence in Five Continents (1998-2007). Cancer Epidemiol. 2016;45:65–70.
17. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1688–1694.
18. Drewnowski A, Popkin BM. The nutrition transition: new trends in the global diet. Nutr Rev. 1997;55(2):31–43.
19. Flemer B, Lynch DB, Brown JM, et al. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut. 2017;66(4):633–643.
20. Gao Z, Guo B, Gao R, et al. Microbiota disbiosis is associated with colorectal cancer. Front Microbiol. 2015;6:20.
21. Nakatsu G, Li X, Zhou H, et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun. 2015;6:8727.
22. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001;292(5519):1115–1118.
23. Morgun A, Dzutsev A, Dong X, et al. Uncovering effects of antibiotics on the host and microbiota using transkingdom gene networks. Gut. 2015;64(11):1732–1743.
24. Engen PA, Green SJ, Voigt RM, et al. The gastrointestinal microbiome: alcohol effects on the composition of intestinal microbiota. Alcohol Res. 2015;37(2):223–236.
25. Sonnenburg ED, Smits SA, Tikhonov M, et al. Diet-induced extinctions in the gut microbiota compound over generations. Nature. 2016;529(7585):212–215.
26. Kohoutova D, Smajs D, Moravkova P, et al. Escherichia coli strains of phylogenetic group B2 and D and bacteriocin production are associated with advanced colorectal neoplasia. BMC Infect Dis. 2014;14:733.
27. Gao R, Kong C, Huang L, et al. Mucosa-associated microbiota signature in colorectal cancer. Eur J Clin Microbiol Infect Dis. 2017;36(11):2073–2083.
28. von Rosenvinge EC, O’May GA, Macfarlane S, et al. Microbial biofilms and gastrointestinal diseases. Pathog Dis. 2013;67(1):25–38.
29. Dejea CM, Wick EC, Hechenbleikner EM, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci U S A. 2014;111(51):18321–18326.
30. Johnson CH, Spilker ME, Goetz L, et al. Metabolite and microbiome interplay in cancer immunotherapy. Cancer Res. 2016;76(21):6146–6152.
31. Benedix F, Kube R, Meyer F, et al. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010;53(1):57–64.
32. Purcell RV, Visnovska M, Biggs PJ, et al. Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer. Sci Rep. 2017;7(1):11590.
33. Mehta RS, Nishihara R, Cao Y, et al. Association of dietary patterns with risk of colorectal cancer subtypes classified by fusobacterium nucleatum in tumor tissue. JAMA Oncol. 2017;3(7):921–927.
34. Larsson SC, Wolk A. Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int J Cancer. 2006;119(11):2657–2664.
35. Magalhaes B, Peleteiro B, Lunet N. Dietary patterns and colorectal cancer: systematic review and meta-analysis. Eur J Cancer Prev. 2012;21(1):15–23.
36. Wu K, Hu FB, Fuchs C, et al. Dietary patterns and risk of colon cancer and adenoma in a cohort of men (United States). Cancer Causes Control. 2004;15(9):853–862.
37. Mehta RS, Song M, Nishihara R, et al. Dietary patterns and risk of colorectal cancer: analysis by tumor location and molecular subtypes. Gastroenterology. 2017;152(8):1944–53 e1.
38. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138(6):2073–87.e3.
39. Lee MS, McGuffey EJ, Morris JS, et al. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. Br J Cancer. 2016;114(12):1352–1361.
40. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58(1):90–96.
41. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96(15):8681–8686.
42. Colussi D, Brandi G, Bazzoli F, et al. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci. 2013;14(8):16365–16385.
43. Kudryavtseva AV, Lipatova AV, Zaretsky AR, et al. Important molecular genetic markers of colorectal cancer. Oncotarget. 2016;7(33):53959–53983.
44. Sideris M, Papagrigoriadis S. Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer. Anticancer Res. 2014;34(5):2061–2068.
45. Ogino S, Kawasaki T, Kirkner GJ, et al. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn. 2007;9(3):305–314.
46. Carethers JM, Jung BH. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology. 2015;149(5):1177–90.e3.
47. Kane MF, Loda M, Gaida GM, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997;57(5):808–811.
48. Ang PW, Loh M, Liem N, et al. Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer. 2010;10:227.
49. Missiaglia E, Jacobs B, D’Ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25(10):1995–2001.
50. Lan YT, Jen-Kou L, Lin CH, et al. Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers. J Surg Oncol. 2015;111(7):905–910.
51. Rowan A, Halford S, Gaasenbeek M, et al. Refining molecular analysis in the pathways of colorectal carcinogenesis. Clin Gastroenterol Hepatol. 2005;3(11):1115–1123.
52. Jacobs B, De Roock W, Piessevaux H, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 2009;27(30):5068–5074.
53. Bendardaf R, Buhmeida A, Hilska M, et al. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res. 2008;28(6b):3865–3870.
54. Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61(6):847–854.
55. Worthley DL, Whitehall VL, Buttenshaw RL, et al. DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer. Oncogene. 2010;29(11):1653–1662.
56. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–1356.
57. Weiss JM, Pfau PR, O’Connor ES, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results–Medicare data. J Clin Oncol. 2011;29(33):4401–4409.
58. Sinicrope FA, Mahoney MR, Smyrk TC, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013;31(29):3664–3672.
59. Venook AP, Niedzwiecki D, Innocenti F, et al. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). Am Soc Clin Oncol. 2016.
60. Van Cutsem E, Lenz HJ, Kohne CH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015;33(7):692–700.
61. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–1075.
62. Boeckx N, Toler A, de Beeck KO, et al. Primary tumor sidedness impacts on prognosis and treatment outcome: results from three randomized studies of panitumumab plus chemotherapy versus chemotherapy or chemotherapy plus bevacizumab in 1st and 2nd line RAS/BRAF WT mCRC. Eur Soc Med Oncol. 2016;27.
63. Loupakis F, Yang D, Yau L, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107(3).
64. Lenz H-J, Lee F-C, Yau L, et al. MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). Am Soc Clin Oncol. 2016;34:493.
65. Houts AC, Ogale S, Zafar Y, et al. Progression-free survival in patients receiving chemotherapy alone (C) or chemotherapy with bevacizumab (CB) for first-line treatment of KRAS mutant metastatic colorectal cancer in community oncolo gy settings. J Gastrointest Cancer. 2017. DOI:10.1007/s12029-017-0017-8.
66. Brule SY, Jonker DJ, Karapetis CS, et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer. 2015;51(11):1405–1414.
67. Boeckx N, Koukakis R, Op de Beeck K, et al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol. 2017;28(8):1862–1868.
68. Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2016. DOI:10.1001/jamaoncol.2016.3797.